Skip to main content
. 2017 Jan 18;12(1):e0170432. doi: 10.1371/journal.pone.0170432

Table 2. Area and sex-adjusted seroprevalence of anti-HAV from 2005 to 2014*.

Age (year) 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
0–9 33.4 52.7 42.4 50.7 69.8 65.8 53.9 71.0 65.4 67.7
10~19 15.4 19.0 20.0 25.5 23.2 19.0 26.4 33.8 35.4 35.2
20~29 22.5 29.2 19.1 17.2 11.9 8.7 13.3 16.2 16.3 20.2
30~39 69.6 67.6 63.8 58.6 48.4 40.7 37.3 34.3 32.1 32.4
40~49 97.9 96.7 94.7 91.4 89.1 87.9 86.1 84.1 80.8 79.3
50~59 98.7** 98.2** 98.0** 99.0** 98.8** 98.7 98.7 98.4 98.0 98.1
60~ 99.2 98.1 99.3 99.5 99.6
Overall 65.6 68.2 64.9 65.1 63.8 61.0 60.5 62.9 61.6 62.2

HAV, hepatitis A virus.

* Seroprevalence of anti-HAV was adjusted by area from 2005 to 2009 and by area and gender from 2010 to 2014

**Persons in their fifties and over sixty were grouped together from 2005 to 2009 because of the small number and similar seroprevalence.